Not so sure about the significance of their royalties for the BACE program (they got it from the Pharmacopeia merger). Would be surprised if it is bigger then 2%.
And I would actually be surprised if royalties aren't a lot higher than 2%. This isn't analogous to their Captisol licensing deals where they are just applying their tech to other companies' drugs. I assume the BACE was a NCE discovered at PCOP which LGND ultimately acquired rights to. As such, they should be entitled to much better economics (at least mid-single digits) one would think.
Edit: I take the aforementioned back given what I found was discussed (see following replies also) in: #msg-77512312. So, not a NCE at PCOP but they aided in the discovery of the BACE so really hard to know for sure exactly where the royalty winds up at.